anti-CXCR3 antibody

Anti-CXCR3 antibodies are a class of monoclonal antibodies designed to target and inhibit the C-X-C Motif Chemokine Receptor 3 (CXCR3), a G protein-coupled receptor primarily expressed on activated T cells, natural killer (NK) cells, and certain myeloid populations. CXCR3 is activated by the chemokines CXCL9, CXCL10, and CXCL11, which are often upregulated in inflammatory and neoplastic conditions. In the context of glioblastoma, research from institutions like UCSF has demonstrated that CXCR3 signaling plays a role in tumor-induced changes to bone marrow hematopoiesis. Specifically, CXCR3 blockade has been shown to inhibit the accelerated maturation of neutrophils and promote their polarization into antitumoral hybrid neutrophil-dendritic cells. Preclinical studies indicate that administration of anti-CXCR3 antibodies can slow tumor growth and prolong survival by reversing these systemic immune alterations. While several anti-CXCR3 candidates have been explored for autoimmune and inflammatory diseases, their application in oncology represents an emerging area of therapeutic interest.

Other names

anti-CXCR3anti-CXCR-3anti-CXCR 3CXCR3 antibodyCXCR-3 antibodyCXCR 3 antibodyCXCR3 antagonist antibodyCXCR-3 antagonist antibodyCXCR 3 antagonist antibodyanti-CXCR3 antibodyanti-CXCR-3 antibodyanti-CXCR 3 antibody